Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Anti-CD18 mAb (Genentech/Roche).

¹Taro Pharmaceuticals USA Inc, Hawthorne, NY, USA. wbrown@taropharma.com

Idrugs : the Investigational Drugs Journal

|August 2, 2005

Summary

This summary is machine-generated.

Genentech and Roche

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Modeling community COVID-19 transmission risk associated with U.S. universities.

Scientific reports·2023

Same author

Dynamics of data availability in disease modeling: An example evaluating the trade-offs of ultra-fine-scale factors applied to human West Nile virus disease models in the Chicago area, USA.

PloS one·2021

Same author

Light Harvesting with Guide-Slide Superabsorbing Condensed-Matter Nanostructures.

The journal of physical chemistry letters·2019

Same author

Iris yellow spot virus on Onion in Colorado.

Plant disease·2019

Same author

Assessing human risk of illness with West Nile virus mosquito surveillance data to improve public health preparedness.

Zoonoses and public health·2017

Same author

THE EVOLUTIONARY HISTORY OF PARTHENOGENETIC CNEMIDOPHORUS LEMNISCATUS (SAURIA: TEIIDAE). II. MATERNAL ORIGIN AND AGE INFERRED FROM MITOCHONDRIAL DNA ANALYSES.

Evolution; international journal of organic evolution·2017

Same journal

Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection.

IDrugs : the investigational drugs journal·2010

Same journal

Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures.

IDrugs : the investigational drugs journal·2010

Same journal

LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome.

IDrugs : the investigational drugs journal·2010

Same journal

Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis.

IDrugs : the investigational drugs journal·2010

Same journal

Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.

IDrugs : the investigational drugs journal·2010

Same journal

Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.

IDrugs : the investigational drugs journal·2010

See all related articles

Area of Science:

Immunology
Cardiology
Pharmacology

Background:

Leukocyte adhesion inhibition via anti-CD18 antibodies is a potential therapy for inflammatory conditions.
Reperfusion injury, particularly myocardial infarction, is a target indication.

Purpose of the Study:

To evaluate the efficacy of an anti-CD18 humanized monoclonal antibody (rhuMAb) in treating myocardial infarction.
To assess the potential of CD18 inhibition for reperfusion injury.

Main Methods:

Phase II clinical trial involving 415 patients with myocardial infarction.
Planned Phase II studies for reperfusion injury in thrombolytic-treated patients.

Main Results:

Preliminary results from the Phase II trial for myocardial infarction did not meet primary objectives.

Related Experiment Videos

The company is evaluating the trial data and its implications.

Conclusions:

The anti-CD18 antibody did not meet primary objectives in the Phase II myocardial infarction trial.
Further investigation and data analysis are pending to determine the drug's future development and market potential.